Renalytix (RENX) AI Stock Analysis

• Market Cap: £25.13M
• Dividend Yield: N/A
• Average Volume (3M): 10.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -4.48%
• EPS Growth: 61.09%
• Country: UK
• Employees: 102
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 437,018,680
• 10 Day Avg. Volume: 3,807,103
• 30 Day Avg. Volume: 10,033,489
• PEG Ratio: 0.01
• Price to Book (P/B): -1.38
• Price to Sales (P/S): 3.23
• P/FCF Ratio: -0.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 5.50p ▼(-6.78% Downside)

The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and a bearish technical trend (price below key moving averages and negative MACD). Positive corporate updates and oversold signals provide some support, but they do not offset current financial and trend risk.

Renalytix Business Overview & Revenue Model

Company Description

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

How the Company Makes Money

Renalytix makes money primarily through the commercialization of its KidneyIntelX diagnostic platform. The company's revenue model involves partnerships with healthcare providers, hospitals, and insurance companies to implement and integrate KidneyIntelX into their patient care systems. By offering a subscription-based or per-test pricing model, Renalytix generates revenue whenever its diagnostic solutions are utilized in clinical settings. Additionally, the company may engage in strategic collaborations with pharmaceutical companies, leveraging its technology for drug development and clinical trial support. These partnerships can provide additional revenue streams through licensing agreements, milestone payments, and data sharing arrangements.

Renalytix Financial Statement Overview

Summary

Financials remain high risk despite some improvement: revenue is still very small (~3.0m) and net losses are extremely large (net margin about -680% in FY2025). Cash burn is heavy (operating/free cash flow about -17.9m in FY2025) and equity is negative, indicating ongoing reliance on external funding.

Income Statement

Revenue remains very small but improved in the latest year (FY2025 revenue up ~26% to ~3.0m). Profitability is still extremely weak: despite a much better gross margin in FY2025 (~40% vs ~7% in FY2024), operating and net losses remain large (net margin about -680% in FY2025), indicating the cost base is far above current revenue scale. The positive trajectory in losses versus prior years is a strength, but the business is still far from break-even.

Balance Sheet

The balance sheet shows elevated financial risk, with stockholders’ equity turning negative in FY2024 and remaining negative in FY2025, which limits flexibility and typically implies reliance on external funding. Debt is modest in absolute terms (~8.3m in FY2025) but is high relative to the company’s current asset base and negative equity position. Overall, leverage and capitalization metrics signal a stressed balance sheet despite lower debt than earlier years.

Cash Flow

Cash burn remains heavy: operating cash flow and free cash flow were both about -17.9m in FY2025, improving versus FY2024 (about -30.1m) but still meaningfully negative. Free cash flow deterioration versus the prior year (FY2025 down ~22%) highlights volatility in spending and working-capital needs. Cash generation is not yet supported by operating performance, leaving the company dependent on financing to fund operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.37M	3.00M	2.29M	3.40M	2.97M	1.49M
Gross Profit	468.00K	1.20M	156.00K	701.00K	918.00K	687.00K
EBITDA	-23.07M	-21.30M	-28.52M	-41.71M	-52.69M	-32.69M
Net Income	-23.43M	-20.40M	-33.46M	-45.61M	-45.28M	-34.73M
Balance Sheet
Total Assets	11.44M	6.10M	7.97M	42.12M	63.26M	102.58M
Cash, Cash Equivalents and Short-Term Investments	9.63M	3.70M	4.68M	24.68M	41.33M	74.45M
Total Debt	8.21M	8.30M	8.54M	12.15M	12.34M	352.00K
Total Liabilities	12.81M	13.10M	15.83M	23.66M	20.09M	7.48M
Stockholders Equity	-1.37M	-7.00M	-7.85M	6.97M	30.61M	95.10M
Cash Flow
Free Cash Flow	-23.02M	-17.90M	-30.11M	-32.67M	-46.44M	-26.26M
Operating Cash Flow	-23.02M	-17.90M	-30.11M	-32.67M	-45.74M	-24.63M
Investing Cash Flow	18.00K	0.00	-4.00K	0.00	-694.00K	-741.00K
Financing Cash Flow	26.88M	16.00M	10.25M	16.39M	25.52M	77.24M

Renalytix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RENX, the sentiment is Negative. The current price of 5.9 is below the 20-day moving average (MA) of 6.12, below the 50-day MA of 6.29, and below the 200-day MA of 7.25, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 27.03 is Positive, neither overbought nor oversold. The STOCH value of 17.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:RENX.

Renalytix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKF	67 Neutral	£106.30M	18.22	8.71%	―	-1.43%	28.57%
VRCI	58 Neutral	£10.97M	-0.30	-122.54%	―	-57.03%	-15.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	47 Neutral	£11.07M	-1.16	-153.92%	―	90.42%	79.21%
RENX	43 Neutral	£25.13M	-0.40	425.97%	―	-4.48%	61.09%
PRM	42 Neutral	£6.31M	-1.63	―	―	12.19%	18.12%
OBD	38 Underperform	£11.80M	-0.29	-407.49%	―	72.17%	79.03%

Renalytix Corporate Events

Renalytix Adds Three U.S. Kidney Care Integrations and Deepens Tempus AI Collaboration

Renalytix has expanded the clinical footprint of its kidneyintelX.dkd test in the US by completing three new electronic health record-integrated deployments with regional kidney care providers in New York, Florida and Tennessee, with testing now underway and a focus on one-click ordering to encourage gradual growth in utilisation. The company is pursuing a measured, resource-efficient rollout strategy and deepening its collaboration with Tempus AI to integrate kidneyintelX.dkd within major health systems’ electronic records and data infrastructures, supporting future geographic and clinical expansion, while simultaneously stepping up investor engagement at the J.P. Morgan Healthcare Conference ahead of a wider trading and corporate update expected in February 2026.

The most recent analyst rating on (GB:RENX) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.

Renalytix Secures Shareholder Support at AGM and Advances Kidney Disease Diagnostics

Renalytix announced that all resolutions were passed at its Annual General Meeting, reflecting strong shareholder support. The company continues to advance its kidneyintelX.dkd test, which has shown significant improvements in diagnosis and treatment rates for kidney disease, and is now fully reimbursed by Medicare, enhancing its market positioning and impact on healthcare systems.

Renalytix Expands Kidney Disease Test Adoption and Strategic Partnerships

Renalytix has provided an update on its strategic initiatives ahead of its Annual General Meeting, highlighting the progress in expanding the adoption of its kidneyintelX.dkd test across key states in the U.S. The company has secured a significant partnership with Tempus AI Inc to enhance patient and clinician access to its test, aiming to drive substantial growth through strategic partnerships and EHR integrations. Additionally, Renalytix is transitioning to a new laboratory facility to increase testing capacity and reduce operational costs, positioning the company for sustainable revenue growth and long-term value creation for shareholders.

Renalytix’s KidneyIntelX.dkd Test Gains Recognition for Advancing CKD Management

Renalytix announced the publication of pivotal data on its kidneyintelX.dkd test in the Diabetes Care Journal, highlighting its clinical utility in chronic kidney disease management. The study demonstrated that the test provides improved risk classification and significant risk reduction when used with SGLT2i therapy, supporting personalized patient care. The publication coincides with presentations at the American Society of Nephrology Kidney Week, reinforcing the test’s value in precision medicine and integrated care management, ultimately leading to better patient outcomes.

Renalytix Publishes 2025 Annual Report and Expands Kidney Disease Test Deployment

Renalytix has published its Annual Report for the year ending June 2025 and announced the Notice of its 2025 Annual General Meeting. The company continues to expand the deployment of its kidneyintelX.dkd test, which has shown significant improvements in diagnosis and treatment rates for kidney disease. The test is now fully reimbursed by Medicare and recommended in international clinical guidelines, reinforcing Renalytix’s position in the healthcare industry.

Renalytix Reports Strong Fiscal 2025 Results and Strategic Expansion

Renalytix announced its audited financial results for fiscal year 2025, highlighting a 30% increase in total revenues to $3 million and a 54% decrease in underlying EBITDA loss. The company achieved significant operational improvements, including a 50% reduction in laboratory test turnaround time and successful strategic partnerships with Tempus AI and MVP Health Care to expand the availability of kidneyintelX.dkd testing. These developments position Renalytix as a leader in chronic kidney disease management, with plans for further expansion into new territories and continued integration with electronic medical record systems to enhance patient identification and testing adoption.

Renalytix Secures £860k in R&D Tax Credits

Renalytix has confirmed the receipt of £860k in Research and Development Tax Credits for work completed in the fiscal years ending June 2023 and June 2024. This financial boost is expected to support the company’s ongoing operations and enhance its industry positioning as a leader in kidney disease diagnostics. The receipt of these credits underscores the company’s commitment to innovation and may have positive implications for stakeholders by reinforcing the financial stability and continued development of its prognostic tools.